Synexus achieves record with more than 10,000 patients enrolled in clinical studies
Synexus has found that its hub site model is increasingly being taken up by the pharma industry as it dramatically reduces costs - often by a factor of 10 - increases the quality of the data and speeds up recruitment.
More than 25 clinical trials are presently being carried out at hub sites in the UK, Poland, Hungary, Bulgaria, India and South Africa, into a wide variety of therapeutic areas including osteoporosis, hypertension, cancer prevention, diabetes, sexual dysfunction, cardiac disease, urinary incontinence, migraine and osteoarthritis.
Michael Fort CEO of Synexus commented, "We are really pleased to have achieved this milestone of 10,000 patients. We are hoping by next year we will have doubled this number as we increase the capacity of our existing hub sites and open new sites in the US and Eastern Europe. This expansion is being driven from industry which wants to reduce costs and professionalise the recruitment and running of late stage clinical trials."
Have more questions? Contact us for more information
